SIC
NRIX icon

SJS Investment Consulting’s Nurix Therapeutics NRIX Stock Holding History

SJS Investment Consulting’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$949 – 2543
2025
Q4 		$949 Hold
50
– – ﹤0.01% 1321
2025
Q3 		$462 Hold
50
– – ﹤0.01% 1259
2025
Q2 		$570 Hold
50
– – ﹤0.01% 1071
2025
Q1 		$594 Buy
+50
New +$836 ﹤0.01% 1188

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

SJS Investment Consulting's NRIX Position: Q1 2026 in Review

SJS Investment Consulting sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 50 shares — an estimated $949 sold.

SJS Investment Consulting first reported a position in NRIX in Q1 2025 and held it in 4 quarters. The position peaked at $949 in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • SJS Investment Consulting reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 50 Nurix Therapeutics shares in Q1 2026, an estimated $949.
  • SJS Investment Consulting first reported a position in Nurix Therapeutics in Q1 2025 and held it in 4 quarters.
  • SJS Investment Consulting's Nurix Therapeutics position peaked at $949 in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.